Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C

• DOI: 10.1111/hepr.12910
• Publication Date: 2017-04-30T14:53:35Z
• Authors: Masanori Atsukawa; Akihito Tsubota; Yohei Koushima; Tadashi Ikegami; Kouji Watanabe; Noritomo Shimada; Shinichi Sato; Keizo Kato; Hiroshi Abe; Tomomi Okubo; Taeang Arai; Norio Itokawa; Chisa Kondo; Shigeru Mikami; Toru Asano; Yoshimichi Chuganji; Yasushi Matsuzaki; Katsuhiko Iwakiri
• Keywords: Ombitasvir; Paritaprevir; Ritonavir; Dasabuvir; Hepatitis C

From a pharmacokinetic viewpoint, the use of ombitasvir/paritaprevir/ritonavir, one standards care for genotype 1b chronic hepatitis C in Japan, could be possible patients with impaired renal function. The aim this study was to assess efficacy and safety combination that have not yet been addressed undergoing dialysis.A retrospective, multicenter evaluated outcome 12-week ombitasvir (non-structural protein [NS]5A inhibitor)/paritaprevir (NS3/4A protease inhibitor)/ritonavir therapy dialysis patients. primary end-point sustained virologic response 12 weeks after (SVR12).The subjects were 31 median age 64 years (range, 49-85 years), including 10 cirrhotic All had an estimated glomerular filtration rate level <15 mL/min/1.73 m2 , defined as end-stage disease (ESRD). Pre-existing resistance-associated substitutions at position L31 Y93 NS5A region detected 0% 3.6% (1/28), respectively. rates rapid response, end-of-treatment SVR12 93.5% (29/31), 100% (31/31), 96.8% (30/31), incidence adverse events 35.5% (11/31). Of 11 patients, discontinued treatment due erythema multiforme thereafter relapsed. most frequent event pruritus (6.5%; 2/31).The present suggests ombitasvir/paritaprevir/ritonavir is effective safe ESRD.